BioPharma Dive

BioPharma Dive is one of the most widely read digital newsrooms covering the pharmaceutical and biotechnology industries, delivering daily reporting on drug development, regulatory decisions, deal-making, and commercial strategy to professionals across the life sciences sector.

Published by Industry Dive, the outlet focuses exclusively on the business and science of biopharma, tracking FDA approvals and rejections, clinical pipeline movements, mergers and acquisitions, licensing agreements, and the financial forces shaping major drug developers and emerging biotechs alike. Its editorial coverage spans branded and generic pharmaceuticals, biologics, gene therapies, and cell-based medicines.

BioPharma Dive serves a professional readership of executives, researchers, investors, and policy professionals who need concise, accurate intelligence rather than academic-length analysis. Content is structured around breaking news, in-depth features, and data-driven briefings that help readers track competitive developments across therapy areas including oncology, rare diseases, neuroscience, immunology, and infectious disease.

Industry Dive, BioPharma Dive's parent company, operates a network of vertical trade publications serving multiple B2B sectors. The biopharma title operates out of Washington, DC, and has built a substantial subscriber base of readers opting into its morning briefing newsletter, which is widely cited as a primary source of industry intelligence within life sciences organisations.

Further information is available at biopharmadive.com.